Stoke Therapeutics Stock Performance
| STOK Stock | USD 11.27 0.04 0.35% |
The entity has a beta of 1.43, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Stoke Therapeutics will likely underperform. At this point, Stoke Therapeutics has a negative expected return of -0.27%. Please make sure to validate Stoke Therapeutics' treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Stoke Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Stoke Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in December 2024. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
Actual Historical Performance (%)
One Day Return 0.93 | Five Day Return (17.76) | Year To Date Return 94.8 | Ten Year Return (55.36) | All Time Return (55.36) |
Last Split Factor 1:9 | Last Split Date 2019-06-06 |
1 | Redmile Group, LLC Expands Stake in Atara Biotherapeutics Inc | 09/13/2024 |
2 | Disposition of 1937500 shares by Skorpios Trust of Stoke Therapeutics at 14.05 subject to Rule 16b-3 | 09/19/2024 |
3 | Skorpios Trust Reduces Stake in Stoke Therapeutics Inc | 09/23/2024 |
4 | Stoke Therapeutics, Inc. Receives Average Rating of Moderate Buy from Brokerages - MarketBeat | 09/27/2024 |
5 | Disposition of 10000 shares by Ticho Barry of Stoke Therapeutics at 12.0648 subject to Rule 16b-3 | 10/01/2024 |
6 | Stoke therapeutics executive sells 120k in stock | 10/02/2024 |
7 | Stoke Therapeutics, Inc. Expected to Beat Earnings Estimates What to Know Ahead of Q3 Release | 10/29/2024 |
8 | Disposition of 10000 shares by Ticho Barry of Stoke Therapeutics at 12.6803 subject to Rule 16b-3 | 11/01/2024 |
9 | Stoke Therapeutics, Inc. Reports Q3 Loss, Tops Revenue Estimates | 11/05/2024 |
10 | Stoke Therapeutics Earns Buy Rating from Needham Company LLC | 11/06/2024 |
11 | Acquisition by Ticho Barry of 10000 shares of Stoke Therapeutics at 0.6 subject to Rule 16b-3 | 11/07/2024 |
12 | CV Sciences and Stoke Therapeutics Head to Head Review | 11/08/2024 |
13 | Stoke Therapeutics May Find a Bottom Soon, Heres Why You Should Buy the Stock Now | 11/20/2024 |
| Begin Period Cash Flow | 114.1 M |
Stoke |
Stoke Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,399 in Stoke Therapeutics on August 23, 2024 and sell it today you would lose (272.00) from holding Stoke Therapeutics or give up 19.44% of portfolio value over 90 days. Stoke Therapeutics is currently does not generate positive expected returns and assumes 3.6729% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Stoke, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Stoke Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Stoke Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Stoke Therapeutics, and traders can use it to determine the average amount a Stoke Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0733
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | STOK |
Estimated Market Risk
| 3.67 actual daily | 32 68% of assets are more volatile |
Expected Return
| -0.27 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Stoke Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Stoke Therapeutics by adding Stoke Therapeutics to a well-diversified portfolio.
Stoke Therapeutics Fundamentals Growth
Stoke Stock prices reflect investors' perceptions of the future prospects and financial health of Stoke Therapeutics, and Stoke Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Stoke Stock performance.
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (6.13) % | ||||
| Current Valuation | 362.15 M | ||||
| Shares Outstanding | 52.97 M | ||||
| Price To Book | 2.58 X | ||||
| Price To Sales | 35.78 X | ||||
| Revenue | 8.78 M | ||||
| Gross Profit | 12.4 M | ||||
| EBITDA | (112.3 M) | ||||
| Net Income | (104.7 M) | ||||
| Cash And Equivalents | 275.63 M | ||||
| Cash Per Share | 6.99 X | ||||
| Total Debt | 6.83 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 10.46 X | ||||
| Book Value Per Share | 4.38 X | ||||
| Cash Flow From Operations | (81.07 M) | ||||
| Earnings Per Share | (2.08) X | ||||
| Market Capitalization | 599.06 M | ||||
| Total Asset | 228.34 M | ||||
| Retained Earnings | (401.85 M) | ||||
| Working Capital | 184.52 M | ||||
About Stoke Therapeutics Performance
By examining Stoke Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Stoke Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Stoke Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1 K | 903 | |
| Return On Tangible Assets | (0.46) | (0.48) | |
| Return On Capital Employed | (0.58) | (0.55) | |
| Return On Assets | (0.46) | (0.48) | |
| Return On Equity | (0.66) | (0.62) |
Things to note about Stoke Therapeutics performance evaluation
Checking the ongoing alerts about Stoke Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Stoke Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Stoke Therapeutics generated a negative expected return over the last 90 days | |
| Stoke Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 8.78 M. Net Loss for the year was (104.7 M) with profit before overhead, payroll, taxes, and interest of 12.4 M. | |
| Stoke Therapeutics currently holds about 275.63 M in cash with (81.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.99. | |
| Over 96.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: Stoke Therapeutics May Find a Bottom Soon, Heres Why You Should Buy the Stock Now |
- Analyzing Stoke Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Stoke Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Stoke Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Stoke Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Stoke Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Stoke Therapeutics' stock. These opinions can provide insight into Stoke Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stoke Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stoke Therapeutics. If investors know Stoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Stoke Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Revenue Per Share 0.328 | Quarterly Revenue Growth 0.479 | Return On Assets (0.28) | Return On Equity (0.52) |
The market value of Stoke Therapeutics is measured differently than its book value, which is the value of Stoke that is recorded on the company's balance sheet. Investors also form their own opinion of Stoke Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Stoke Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Stoke Therapeutics' market value can be influenced by many factors that don't directly affect Stoke Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Stoke Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Stoke Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stoke Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.